Explore bioanalytical strategies that support COVID-19 therapeutic and vaccine development.

As the rapid development of COVID-19 therapeutics and vaccines accelerated innovation, robust bioanalytical methods remained essential for generating reliable, regulatory-compliant data. This webinar examines current approaches to immunogenicity testing and highlights an alternative surrogate virus neutralization test (sVNT) that enables rapid, high-throughput assessment of neutralizing antibodies without the need for biosafety level 3 containment.

Topics include:

• Current bioanalytical approaches for COVID-19 therapeutic and vaccine clinical trials
• How surrogate virus neutralization tests (sVNT) compare with conventional virus neutralization assays
• The advantages of high-throughput, automated neutralizing antibody testing
• Regulatory considerations for immunogenicity testing and emerging analytical technologies
• Strategies for accelerating clinical development while maintaining robust bioanalytical standards

As infectious disease research continues to evolve, reliable immunogenicity testing remains critical for supporting vaccine and therapeutic development. Discover how innovative neutralizing antibody testing approaches can improve efficiency while delivering high-quality data for clinical research.